Clinical trial

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

NCT05856981

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-04-03

PhasePHASE1

Study timeline

Study start (actual)2023-04-03Date precision: day

Registry last updated2025-12-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Solid Tumor, Adultunresolved

Metastatic Solid Tumorunresolved

Refractory Cancerunresolved

CRC, Colorectal Cancerunresolved

RCC, Clear Cell Adenocarcinomaunresolved

NSCLC (Advanced Non-small Cell Lung Cancer)unresolved

Endometrial Cancerunresolved

Interventions

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

Sponsors & collaborators

Sairopa B.V.lead sponsor

Mapped research locations

MadridSpain2 St LouisMissouri, United States1 DetroitMichigan, United States1 FairfaxVirginia, United States1 CantonOhio, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05856981 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.